Tianjin's CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO
publication date: Mar 20, 2019
Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas. Its Ebola vaccine has been approved for use, and the company's meningitis and a meningococcal vaccines are near-NDA stage. Both candidates have demonstrated superior safety profiles and immunogenicity in their Phase III trials. CanSino is the seventh China biopharma, and the first vaccine company, to IPO in Hong Kong under its pre-revenue rules. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.